Infection risk mitigation with complement inhibitors in kidney disease
Nephrology Dialysis Transplantation · 23.05.2026
DOI: 10.1093/ndt/gfag113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 23.05.2026. Verfasst von Mathilde Berghmans und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University Hospitals Namur (CHU UCL Namur), Namur, Belgium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: AstraZeneca Foundation, Fondation Mont-Godinne.
Abstract (Originalsprache)
Complement inhibitors are increasingly used in kidney diseases, ranging from complement-mediated thrombotic microangiopathies to glomerulonephritis. Because complement is central to host defence against encapsulated bacteria, therapeutic blockade creates a predictable infectious vulnerability requiring structured prevention strategies. This narrative review integrates complement biology with evidence from pivotal kidney trials, pharmacovigilance analyses, and national public health recommendations to propose a pragmatic framework for mitigating infection-risk in patients treated with complement inhibitors. Key complement functions (C3b-mediated opsonization, C3a/C5a-driven inflammation, and membrane attack complex formation) underlie target-specific patterns of infectious risk. Terminal C5 inhibition (eculizumab, ravulizumab) confers a reproducible exposure-adjusted risk of invasive meningococcal disease, including rare but documented infection-related mortality, with breakthrough infections reported despite vaccination. In contrast, inhibition at the level of C3/C3b or the alternative pathway amplification loop has not, to date, demonstrated a consistent encapsulated-pathogen signal in phase 3 kidney trials, although follow-up remains limited and rare events cannot be excluded. Effective prevention relies on target-adapted vaccination against encapsulated bacteria, consideration of antimicrobial prophylaxis when therapy must begin before vaccine protection is established—and in selected higher-risk settings during sustained complement blockade—and structured patient education with rapid-access pathways for febrile illness. Chronic kidney disease, dialysis exposure, transplantation, and concomitant immunosuppression may further amplify infectious risk and attenuate vaccine responsiveness. Infection risk under complement inhibition is target-dependent and not eliminated by vaccination alone, particularly with terminal C5 blockade. Mechanism-informed, kidney-specific prevention strategies are essential as complement therapies expand into routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases, University Hospitals Namur (CHU UCL Namur), Namur, Belgium.
- Division of Nephrology, University Hospitals Namur (CHU UCL Namur), Namur, Belgium.
- Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
- Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria.
- de Duve Institute, UCLouvain, Brussels, Belgium.
ORCID-Profile: Safak Mirioglu, Johann Morelle
Förderung
- AstraZeneca Foundation
- Fondation Mont-Godinne
Zitieren
APA
Berghmans, M., Seghers, F., Mirioglu, S., Kronbichler, A., & Morelle, J. (2026). Infection risk mitigation with complement inhibitors in kidney disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag113
Vancouver
Berghmans M, Seghers F, Mirioglu S, Kronbichler A, Morelle J. Infection risk mitigation with complement inhibitors in kidney disease. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag113
BibTeX
@article{Berghmans2026,
author = {Berghmans, Mathilde and Seghers, François and Mirioglu, Safak and Kronbichler, Andreas and Morelle, Johann},
title = {Infection risk mitigation with complement inhibitors in kidney disease},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag113}
}
EUVIMED